Back
Bertoni_2021_MDPI_cancers
Journal article

PI3Kδinhibitors as immunomodulatory agents for the treatment of lymphoma patients

  • Tarantelli, Chiara ORCID Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, UniversitĂ  della Svizzera italiana, Switzerland
  • Argnani, Lisa ORCID IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy - Istituto di Ematologia “SerĂ gnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, UniversitĂ  degli Studi di Bologna, Bologna, Italy
  • Zinzani, Pier Luigi ORCID IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy - Istituto di Ematologia “SerĂ gnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, UniversitĂ  degli Studi di Bologna, Bologna, Italy
  • Bertoni, Francesco ORCID Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, UniversitĂ  della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
Show more…
  • 2021
Published in:
  • Cancers. - 2021, vol. 13, p. 5535.
Lymphoma
PI3K inhibitors
T-cells
B-cells
Macrophages
Chemokine
Cancer
Tumor
Immune checkpoint inhibitors
English The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδinhibitors exert on the immune system with a particular focus on the T-cell compartment.
Collections
Language
  • English
Classification
Medicine
License
CC BY
Open access status
gold
Identifiers
Persistent URL
https://n2t.net/ark:/12658/srd1322802
Statistics
Document views: 42 File downloads:
  • Bertoni_2021_MDPI_cancers.pdf: 99